Poor
Poorly Aligned
Patient Risk:
Low
Summary
The AI response largely omits and misrepresents approved FDA labeling. A minority of claims align with approved indications and safety information; many statements are not supported by the labeling, and no dosage/administration details are provided.
Category Scores
Accurate Statements
Tigecycline is a broad-spectrum antibiotic.
12.1
Overuse of tigecycline has raised concerns about antibiotic resistance.
5.12
Overuse of tigecycline has raised concerns about potential harm to patients.
5.3, 5.4, 5.9
Tigecycline is also known as Tygacil.
1.1
Tigecycline is a glycylcycline antibiotic.
12.1
Tigecycline is approved for complicated skin and skin structure infections (cSSSI).
1.1
Tigecycline is approved for community-acquired bacterial pneumonia (CABP).
1.3
Overuse of tigecycline can lead to the development of resistant bacteria.
5.12
Tigecycline has been associated with liver damage.
5.4
Tigecycline has been associated with allergic reactions.
5.3
Unsupported Statements
Tigecycline has revolutionized the treatment of complex infections.
Labeling does not use evaluative or marketing language about revolutionizing treatment.
Tigecycline was developed by Wyeth Pharmaceuticals (now a part of Pfizer).
Manufacturing history is not a labeling claim.
Tigecycline was approved by the FDA in 2005.
FDA approval date is not stated in the provided labeling excerpts.
Tigecycline is often prescribed for indications not approved by the FDA.
Labeling denotes approved indications; off-label use is not endorsed.
Hospital-acquired pneumonia is an off-label indication for tigecycline.
Label lists only cSSSI and CABP as approved indications.
Ventilator-associated pneumonia is an off-label indication for tigecycline.
Label lists only cSSSI and CABP as approved indications.
Tigecycline has been associated with adverse events, such as gastrointestinal problems.
GI adverse events are not explicitly claimed in the cited sections.
Overuse of tigecycline can lead to increased healthcare costs due to prolonged hospital stays and additional treatments.
Economic impact is not addressed in labeling.
Reversing tigecycline overuse requires improved antibiotic stewardship.
Label does not prescribe stewardship strategies.
Healthcare professionals must be educated about the risks and limitations of tigecycline.
Not a labeling directive.
Healthcare professionals must use antibiotics judiciously.
General stewardship messaging not stated as labeling directive.
Regular monitoring of antibiotic use and resistance patterns can help identify areas for improvement.
Not addressed in labeling.
Developing and promoting alternative treatments for complex infections can reduce the reliance on tigecycline.
Not addressed in labeling.
Educating patients about the risks of antibiotic overuse and the importance of antibiotic stewardship can empower them to make informed decisions.
Not addressed in labeling.
The overuse of tigecycline is a significant concern.
Label does not characterize 'overuse' in these terms.
Addressing overuse through improved antibiotic stewardship and education is essential.
Not addressed in labeling.
A hospital's implementation of antibiotic stewardship programs, including education and monitoring, led to a significant reduction in tigecycline use.
Not addressed in labeling.
Tigecycline overuse is a pressing concern.
Not addressed in labeling.
Antibiotic stewardship is essential for promoting responsible antibiotic use and reducing the overuse of tigecycline.
Not addressed in labeling.
Contradictions
Important Omissions
Dosage and administration details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label documents hepatic, hypersensitivity, and Clostridioides difficile–associated risk; many claims are non-assertive or non-labeled content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Numerous absent/off-label claims and missing dosage information.
Suggested Improvement
Limit claims to approved indications and safety data; include dosage/administration details; avoid off-label framing.